|Neuland Laboratories Limited, engaged in the manufacture of bulk drugs has been incorporated in 1984 as a private limited company. The Company has been promoted by Dr. D.R.Rao, Ph D. in Organic Chemistry from the University of Notre Dame, USA. The company commenced operations in
June 1986 at its plant at Bonthapally Village, Medak District, Andhra Pradesh with a capacity to manufacture 1.2 tonnes per annum (tpa) of Salbutamol sulphate, an anti asthmatic drug and its intermediates such as salbutamol base and bencyl salbutamol.
In 1990 the Company expanded its installed capacity for salbutamol sulphate and its intermediates to 9 tpa. In 1993, the Company completed a project for the manufacture of 2.4 tpa of terbutaline sulphate (Terbutaline), an anti asthmatic drug, 3.6 tpa of labetalol hydrochloride (Labetalol), an anti hypertension drug and for further
expanding the capacity of salbutamol sulphate to 18 tpa. The Company commenced manufacturing ciprofloxacin by utilising part of the additional facilities created for salbutamol sulphate. The total project cost of Rs.346 lacs was financed by a rupee term loan of Rs.260 lacs from ICICI and cash accruals of Rs.86 lacs.
In 1994, the Company completed a project for further diversifying its bulk drug manufacture and set up a new plant at I.D.A. Pashamylaram, Medak district, Andhra Pradesh for the manufacture of 1.5 tpa of enalapril maleate (Enalapril), a cardio-vascular drug, 60 tpa of ranitidine hydrochloride (Ranitidine), an anti-ulcer drug and 66 tpa
of Quinolones (such as Ciprofloxacin, Norfloxacin, Ofloxacin and Pefloxacin), a new generation of anti-bacterial drugs. The project cost of Rs.1570 lacs was financed by rupee term loans of Rs.600 lacs (ICICI - 400, SCICI - 200), equity issue of Rs.870 lacs, state subsidy of Rs.15 lacs and cash accruals of Rs.85 lacs. The commercial production commenced in October 1994. Out of the equity of Rs.870 lacs, Rs.570 lacs was offered to the public (at a premium of Rs.35/- per share). The issue was oversubscribed 70 times and the shares are listed on the
Hyderabad and Bombay Stock Exchanges.
The Company has been granted quality system certification as per ISO 9002-9004, for its Plant at Bonthapally Village, for the manufacture and supply of bulk drugs and intermediates.
The Company has well equipped Research & Development facilities at Bonthapally which has been recognised by the Government of India. The company's R&D department is headed by Dr. C. Sankar Rao who has over 31 years experience in drug and pharmaceutical R&D including 25
years in Indian Drugs and Pharmaceuticals Ltd. (IDPL).
The Company had entered into an agreement with Indian Institute of Chemical Technology (IICT), Hyderabad for process know-how for the manufacture of 2 of its products Ketorolac Tromethamine and Enalapril Maleate on 2nd December 1992.
Neuland Drugs & Pharmaceuticals Private Limited (NDPL), a company set up by the promoters to manufacture bulk drugs, was incorporated in 1988 and merged with Neuland Laboratories Limited, with effect from April 1, 1992 as per the Scheme of Amalgamation approved by the High Court of
Andhra Pradesh on April 6, 1993. As per the scheme, one fully paid up equity share in Neuland Laboratories Limited was exchanged for every seven fully paid up equity shares held in NDPL ranking pari-passu with the existing shares of Neuland.
- Neuland Laboratories Ltd has informed that Ms. Deepika Gupta has joined us as Company Secretary on 13th May 2009 and she will also act as compliance officer of the Company from 13th May 2009 onwards in place of Mr. A. Raghvendracharyulu.
-Neuland Laboratories Ltd Issues Rights in the Ratio of 5:12
--Registered Office of the Company has been shifted to Sanali Info park, 'A' Block, Ground floor,8-2-120/113, Road No.2, Banajara Hills, Hyderabad- 500034 from 204, Meridian plaza 6-3-953/1, Ameerpet, Hyderabad- 500016.
- Board has recommended a Dividend of Rs. 1.20 per share of a face value of Rs. 10 each.
- Neuland Labs Track Record of cGMP Excellence complemented by 2013 CMO Leadership Award for Regulatory Excellence.
- Neuland Labs Inaugurates new manufacturing facility constructed for its Collaboration with Mitsubishi Healthcare Unit API Corporation.
- Board has recommended a Dividend of 30% (including a special dividend of 15%) at Rs. 3 per equity share on a face value of Rs. 10 each,
-Neuland Laboratories has announced Rights in the Ratio of 4:25
-Company has entered into a Joint Development Agreement (ÂJDAÂ) with Phoenix Embassy Techno Zone Private Limited.